; and (D) an accounting of adverse events (including hyperimmune response), including further disaggregation by history of infection; and (2) assess the prevalence of each such health condition by each age group specified in paragraph (1)(B) among the unvaccinated population for each of years 2017, 2018, and 2019. (c) Report Not later than one year after the date of the enactment of this Act and each year thereafter for the subsequent four years, the Secretary shall submit to the Committees on Armed Services of the House of Representatives and the Senate a report on the results of each study conducted under subsection (a). (d) COVID–19 vaccine defined The term COVID–19 vaccine means a vaccine licensed under section 351 of the Public Health Service Act ( 42 U.S.C. 262 ) or authorized for emergency use under section 564 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360bbb–3 ) for immunization against the virus responsible for COVID–19. 726. GAO study on health care available to certain individuals supporting the missions of United States Forces Japan and Joint Region Marianas (a) Study required The Comptroller General of the United States shall conduct a study to determine whether health care services available to covered individuals are sufficient to support the missions and readiness of United States Forces Japan and Joint Region Marianas. (b) Elements The study under this section shall include the following elements: (1) The assessment of the Comptroller General of the effects of the changes to the administration and management of the military health system— (A) under Defense Health Agency Region Indo-Pacific Administrative Instruction 6025.02, signed on December 22, 2022; and (B) on health care services available to covered individuals through the direct care component of the TRICARE program. (2) An estimate of— (A) the number of covered individuals who in fiscal years 2020 through 2023 received health care services through the military health system on a space-available basis